Pear Therapeutics to Participate in LifeSci Partners HealthTech Symposium

Rhea-AI Summary

Pear Therapeutics, Inc. (NASDAQ: PEAR) announced its participation in the LifeSci Partners HealthTech Symposium on September 20, 2022. CEO Corey McCann, M.D., Ph.D., will join a virtual fireside chat at 12:30 p.m. ET. Interested parties can access a live audio webcast of the event here, and a replay will be available on Pear's website for 30 days post-event.

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the LifeSci Partners HealthTech Symposium on September 20, 2022. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 12:30 p.m. ET.

A live audio webcast of the presentation can be accessed by clicking here and will be made available in the Investors section of Pear’s website at www.peartherapeutics.com. A replay of the webcast will be available on Pear’s website for up to 30 days following the live presentation.

About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas., including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005256/en/

Media and Investors:

Meara Murphy

Senior Director, Corporate Communications

meara.murphy@peartherapeutics.com

Source: Pear Therapeutics, Inc.

FAQ

When is Pear Therapeutics participating in the LifeSci Partners HealthTech Symposium?

Pear Therapeutics will participate in the LifeSci Partners HealthTech Symposium on September 20, 2022.

Who is representing Pear Therapeutics at the symposium?

Corey McCann, M.D., Ph.D., the CEO of Pear Therapeutics, will represent the company at the symposium.

What time is Pear Therapeutics' presentation at the symposium?

Pear Therapeutics' presentation at the symposium is scheduled for 12:30 p.m. ET.

How can I access the webcast of Pear Therapeutics' presentation?

The live audio webcast of Pear Therapeutics' presentation can be accessed via their website or directly through the provided link in the press release.

Will there be a replay of the Pear Therapeutics presentation available?

Yes, a replay of Pear Therapeutics' presentation will be available on their website for up to 30 days following the event.

What is the stock symbol for Pear Therapeutics?

The stock symbol for Pear Therapeutics is PEAR.